Pfizer Inc. PFE announced today that the United States Patent & Trademark Office
has granted Pfizer a reissue patent (U.S. Patent No. RE44048), covering
methods of treating osteoarthritis and other approved conditions with
celecoxib, the active ingredient in Celebrex^®. The reissue patent will expire
on December 2, 2015, which includes six months of pediatric exclusivity. The
basic patent for celecoxib expires on May 30, 2014, which also includes six
months of pediatric exclusivity.
“Continued development of new medicines that enhance patient lives is
supported by protecting intellectual property and innovation,” said Amy
Schulman, executive vice president and general counsel for Pfizer. "We are
pleased with the reissuance of this patent protecting the invention of using
celecoxib to treat osteoarthritis and other approved conditions, and have
initiated legal proceedings to enforce our intellectual property rights
through December 2, 2015.”
Pfizer filed suit today against Teva Pharmaceuticals USA, Inc., Mylan
Pharmaceuticals Inc., Watson Laboratories, Inc., Lupin Pharmaceuticals, USA,
Inc., Apotex Corp., and Apotex, Inc. in the United States District Court for
the Eastern District of Virginia for infringement of the reissue patent. Each
of these generic companies previously filed an abbreviated new drug
application with the United States Food and Drug Administration seeking
approval to market a generic form of celecoxib in the United States beginning
in May 2014, prior to the December 2, 2015 expiration of the reissue patent.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in